3341-35-3

Upstream product

• 3341-36-4 N-(3,4-dimethoxyphenylethyl)-2-phenoxyacetamide 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 122-59-8 2-phenoxyacetic acid 
• 701-99-5 Phenoxyacetyl chloride 

Downstream Products

• 1309235-45-7 C₃₄H₃₃N₃O₁₁S 
• 1309235-21-9 C₃₂H₃₃N₃O₁₁S 
• 1309235-39-9 C₃₄H₃₇N₃O₁₁S 
• 1309235-50-4 C₃₆H₄₁N₃O₁₁S 
• 3341-32-0 6,7-dimethoxy-1-(phenoxymethyl)-1,2,3,4-tetrahydroisoquinoline 
• 1307707-42-1 6,7-dimethoxy-1-phenoxymethyl-2-(1-methylsulfanyl-2-nitrovinyl)-1,2,3,4-tetrahydroisoquinoline 
• 1307707-45-4 6,7-dimethoxy-1-phenoxymethyl-2-(1-(n-octyl)amino-2-nitrovinyl)-1,2,3,4-tetrahydroisoquinoline 
• 1307707-47-6 6,7-dimethoxy-1-phenoxymethyl-2-(1-(phenethyl)amino-2-nitrovinyl)-1,2,3,4-tetrahydroisoquinoline 
• 1307707-70-5 6,7-dimethoxy-1-phenoxymethyl-2-N-(N-nitroguanyl)-1,2,3,4-tetrahydroisoquinoline 
• 1237533-48-0 6,7-dimethoxy-1-(phenoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl(phenyl)methanone 

Relevant academic research and scientific papers

Synthesis and structure activity relationship of tetrahydroisoquinoline- based potentiators of GluN2C and GluN2D containing N-Methyl-D-aspartate receptors

We describe here the synthesis and evaluation of a series of tetrahydroisoquinolines that show subunit-selective potentiation of NMDA receptors containing the GluN2C or GluN2D subunits. Bischler-Napieralski conditions were employed in the key step for the

Synthesis and biological evaluation of a series of 6,7-dimethoxy-1-(3,4- dimethoxybenzyl)-2-substituted tetrahydroisoquinoline derivatives

Multidrug resistance in cancer is a major cause of failure in cancer chemotherapy. In search of new compounds with strong reversal activity and simple molecular structure, we have synthesized a series of compounds in which different substituents were linked to the 2-position of the 6,7-dimethoxy-1-(3, 4-dimethoxybenzyl)-tetrahydroisoquinoline system. Compounds were analyzed for their cytotoxicity by MTT in K562 cell line in vitro, all of the derivatives exhibited little cytotoxic activity. In the meantime, these compounds were evaluated by MTT in K562/A02 cell line in vitro, 6e, 6h and 7c exhibited similar or more potent activities than verapamil with the IC50 values at 0.66, 0.65 and 0.96μM, and with the ratio factor of 24.13, 24.50 and 16.59, respectively.

Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents

Multidrug resistance in tumor cells poses a major obstacle to efficient chemotherapy. Several types of agents have been recognized as multidrug resistance inhibitors, among which the tetrahydroisoquinolines is the most studied. In current study 16 furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline were synthesized. Their cytotoxic activities and effects in reversing multidrug resistance have been evaluated. The results revealed that these compounds had moderate cytotoxic effects. Compounds 7a-f, 7h, and 7l showed higher cytotoxicities than the rest, but lower than adriamycin on K562 cell line. Compounds 7d, 7f, and 7l exhibited potent MDR reversal activities on K562/A02 cell line. The accumulation assay indicated that compounds 7d, 7f, and 7l significantly increased the intracellular accumulation of rhodamine123 in K562/A02 cells. Furthermore, these three compounds produced high concentrations of NO in K562/A02 cells. Potentially, the high concentrations of NO produced by NO donor moieties will lead to an increased cytotoxicity to K562/A02 cells. Our results suggested that compounds 7d, 7f, and 7l had anticancer effects, as well as multidrug resistance reversal effects.